Cargando…

Pharmaceutical policies in Australia and New Zealand

Detalles Bibliográficos
Autor principal:	Babar, Zaheer-Ud-Din
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Keynote Speaker Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603331/ http://dx.doi.org/10.1186/2052-3211-8-S1-K5

Ejemplares similares

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Affordable innovation: future directions in pharmaceutical policy
por: Hill, Suzanne R
Publicado: (2015)

Managing new premium-priced medicines in Europe
por: Permanand, Govin, et al.
Publicado: (2015)

On translating technology research into industrial applications
por: Wong, Stephen T C
Publicado: (2014)

TVET as an important factor in country’s economic development
por: Pavlova, Margarita
Publicado: (2014)

Assisted technology for daily living
por: Tong, Kai-yu Raymond
Publicado: (2014)

Prices of oncology medicines in European countries, Australia and New Zealand
por: Vogler, Sabine, et al.
Publicado: (2015)

The excitement of conducting research and the practical implications
por: Halpern, Georges M
Publicado: (2015)

How to innovate and make successful business
por: Yim, Eric Chi-ming
Publicado: (2015)

The multi-faceted roles of the PI3K-AKT pathway in melanoma
por: Davies, Michael A
Publicado: (2015)

Combining radiation therapy with immunotherapy: clinical translation
por: Formenti, Silvia C
Publicado: (2015)

Surgery in the combination therapies era
por: Mozzillo, Nicola
Publicado: (2015)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

Targeting multiple inhibitory receptors to reverse melanoma-induced T cell dysfunction
por: Zarour, Hassane M
Publicado: (2015)

Role of signal transduction and microRNAs on the immunogenicity of melanoma cells
por: Meyer, Stefanie, et al.
Publicado: (2015)

Advances in adoptive cellular therapy of cancer
por: Stroncek, David
Publicado: (2015)

Molecular and cellular basis for immunomodulation with monoclonal antibodies
por: Melero, Ignacio
Publicado: (2015)

Genetic heterogeneity and transcriptional plasticity drive resistance during immunotherapy and targeted therapy
por: Dummer, Reinard
Publicado: (2015)

The immune-related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2015)

Evolution of resistance to MAPK-targeted therapies
por: Lo, Roger
Publicado: (2015)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015)

Molecular enhancement of sentinel node evaluation
por: Cochran, Alistair J
Publicado: (2015)

Mechanisms of synergy of radiotherapy and immunotherapy
por: Pilones, Karsten A, et al.
Publicado: (2015)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Strategies and designs for combination immune therapy
por: Khleif, Samir
Publicado: (2015)

Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
por: Puzanov, Igor
Publicado: (2015)

MEK + CDK4 a regimen for non-BRAF V6000 melanoma
por: Sosman, Jeff
Publicado: (2015)

Priority medicines for Europe and the World: setting a public-health-based medicines development agenda
por: Wirtz, Veronika J
Publicado: (2015)

Scottish collaboration to integrate medicine therapy between out-patient and in-patient sectors
por: Paterson, Kenneth R
Publicado: (2015)

Diabetes and the diabetic foot in 2011
por: Boulton, Andrew JM
Publicado: (2011)

Diagnosis and management of diabetic neuropathy
por: Boulton, Andrew JM
Publicado: (2011)

Shifting paradigms in the approach to footstrikes, footwear and treatment of the foot
por: Davis, Irene
Publicado: (2011)

Evaluation of the injured runner: developing the clinical hypothesis
por: Davis, Irene
Publicado: (2011)

Gait retraining: altering the fingerprint of gait
por: Davis, Irene
Publicado: (2011)

Why does gout target the foot? The pathogenesis of podagra
por: Roddy, Edward
Publicado: (2011)

Foot pain: common, of consequence, and consulted about
por: Roddy, Edward
Publicado: (2011)

Epidemiology and impact of hallux valgus: more than just bunions
por: Roddy, Edward
Publicado: (2011)

The legacy of Alex Stacoff for foot and footwear biomechanics research
por: Cavanagh, Peter R
Publicado: (2012)

Biomechanics of the ageing foot and ankle
por: Menz, Hylton B
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u9fhl9svqmae9p3t8lua5mt5j5